Literature DB >> 8093628

Total lymphocyte count as a predictor of absolute CD4+ count and CD4+ percentage in HIV-infected persons.

S P Blatt1, C R Lucey, C A Butzin, C W Hendrix, D R Lucey.   

Abstract

OBJECTIVE: To determine whether the total lymphocyte count (TLC) accurately predicts a low absolute CD4+ T-cell count and CD4+ percentage in persons infected with human immunodeficiency virus (HIV).
DESIGN: Retrospective analysis of data collected in the US Air Force HIV Natural History Study.
SETTING: Military medical center that performs annual medical evaluation of all HIV-infected US Air Force personnel. PATIENTS: A total of 828 consecutive patients with no prior history of zidovudine use, evaluated from January 1985 through July 1991. For patients with multiple observations over time, a single data point within each 6-month interval was included in the analysis (N = 2866).
MEASUREMENTS AND MAIN RESULTS: The sensitivity, specificity, and likelihood ratio (LR) of the TLC, in the range of 1.00 x 10(9)/L to 2.00 x 10(9)/L, in predicting an absolute CD4+ T-cell count less than 0.20 x 10(9)/L or a CD4+ percentage less than 20% were calculated. In addition, the LR and pretest probability of significant immunosuppression were used to calculate posttest probabilities of a low CD4+ count for a given TLC value. The LR of the TLC in predicting an absolute CD4+ count < 0.20 x 10(9)/L increased from 2.4 (95% confidence interval, 2.2 to 2.5) for all TLCs less than 2.00 x 10(9)/L, to 33.2 (95% confidence interval, 24.1 to 45.7) for all TLCs less than 1.00 x 10(9)/L. The specificity for this prediction increased from 57% to 97% over this range. The LR also increased from 1.4 (95% confidence interval, 1.3 to 1.6) for all TLCs less than 2.00 x 10(9)/L to 9.7 (95% confidence interval, 7.1 to 13.1) for all TLCs less than 1.00 x 10(9)/L in predicting a CD4+ percentage less than 20%.
CONCLUSIONS: The TLC, between 1.00 x 10(9)/L and 2.00 x 10(9)/L, appears to be a useful predictor of significant immunosuppression as measured by a CD4+ T-cell count less than 0.20 x 10(9)/L in HIV-infected persons. The LR for a given TLC value and the pretest probability of immunosuppression can be used to determine the posttest probability of significant immunosuppression in individual patients. For example, in a patient with a TLC less than 1.50 x 10(9)/L and a pretest probability of 16%, the posttest probability of a low CD4+ T-cell count increases to 53%. In contrast, a TLC greater than 2.00 x 10(9)/L in an individual with a pretest probability of 30% will decrease the posttest probability of a low CD4+ T-cell count to less than 4%. Physicians should find these data useful to help predict the risk for opportunistic infection among HIV-infected persons who present with syndromes that are potentially compatible with opportunistic infection but who have not had recent or prior CD4+ T-cell analysis.

Entities:  

Mesh:

Year:  1993        PMID: 8093628

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  11 in total

1.  Clinical research, prophylaxis, therapy, and care for HIV disease in Africa.

Authors:  K M De Cock; S B Lucas; S Lucas; J Agness; A Kadio; H D Gayle
Journal:  Am J Public Health       Date:  1993-10       Impact factor: 9.308

2.  Total lymphocyte count of 1200 is not a sensitive predictor of CD4 lymphocyte count among patients with HIV disease in Kampala, Uganda.

Authors:  Moses R Kamya; Fred C Semitala; Thomas C Quinn; Allan Ronald; Denise Njama-Meya; Harriet Mayanja-Kizza; Elly T Katabira; Lisa A Spacek
Journal:  Afr Health Sci       Date:  2004-08       Impact factor: 0.927

3.  Absolute lymphocyte count as a surrogate marker for CD4 counts after six months of HAART initiation in a resource-limited setting in India.

Authors:  S Srirangaraj; D Venkatesha
Journal:  Indian J Med Res       Date:  2012-06       Impact factor: 2.375

4.  Comparing absolute lymphocyte count to total lymphocyte count, as a CD4 T cell surrogate, to initiate antiretroviral therapy.

Authors:  Srirangaraj Sreenivasan; Venkatesha Dasegowda
Journal:  J Glob Infect Dis       Date:  2011-07

5.  Absolute lymphocyte count is not a suitable alternative to CD4 count for determining initiation of antiretroviral therapy in fiji.

Authors:  Dashika A Balak; Karen Bissell; Christine Roseveare; Sharan Ram; Rachel R Devi; Stephen M Graham
Journal:  J Trop Med       Date:  2014-10-27

6.  Value of the use of absolute lymphocyte as surrogate for CD4 count in resource poor situations.

Authors:  Oluwafemi Johanson Adegbamigbe; James Olabanji Adewuyi; Philip O Olatunji
Journal:  Niger Med J       Date:  2014-09

7.  Pneumocystis jirovecii prophylaxis in patients treated for high-grade gliomas: a survey among neuro-oncologists.

Authors:  Nebojša Skorupan; Surabhi Ranjan; Seema Mehta; Olga Yankulina; Nathan Nenortas; Stuart Grossman; Xiaobu Ye; Matthias Holdhoff
Journal:  Neurooncol Pract       Date:  2018-11-29

8.  Total Lymphocyte Count as surrogate marker for CD4 Cell Count in HIV-Infected Individuals in Gondar University Hospital, Northwest Ethiopia.

Authors:  Yitayih Wondimeneh; Getachew Ferede; Gizachew Yismaw; Dagnachew Muluye
Journal:  AIDS Res Ther       Date:  2012-07-15       Impact factor: 2.250

9.  Evaluating total lymphocyte count as a surrogate marker for CD4 cell count in the management of HIV-infected patients in resource-limited settings: a study from China.

Authors:  Jieqing Chen; Wei Li; Xiaojie Huang; Caiping Guo; Ran Zou; Qiuying Yang; Hongwei Zhang; Tong Zhang; Hui Chen; Hao Wu
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

10.  Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.

Authors:  Shigeo Shimose; Takumi Kawaguchi; Hideki Iwamoto; Masatoshi Tanaka; Ken Miyazaki; Miki Ono; Takashi Niizeki; Tomotake Shirono; Shusuke Okamura; Masahito Nakano; Hideya Suga; Taizo Yamaguchi; Yoshinori Yokokura; Kazunori Noguchi; Hironori Koga; Takuji Torimura
Journal:  Nutrients       Date:  2020-04-13       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.